Effects of intraventricular methotrexate administration on Cuprizone-induced demyelination in mice

We previously showed that intrathecal administration of methotrexate slowed disability progression in multiple sclerosis patients with progressive disease. In general MS patients with progressive disease respond poorly to anti-inflammatory therapies. In order to better understand the mechanism by wh...

Full description

Bibliographic Details
Main Authors: Andre Michael Mueller, Adam eNassery, Hana eConlon, Xinhe eLiu, Massimiliano eCristofanilli, Esther eJun, Bo Hyung eYoon, Saud Ahmed Sadiq
Format: Article
Language:English
Published: Frontiers Media S.A. 2013-10-01
Series:Frontiers in Molecular Neuroscience
Subjects:
EAE
Online Access:http://journal.frontiersin.org/Journal/10.3389/fnmol.2013.00034/full
id doaj-5065821b3c524cb7aec6064292bc4e78
record_format Article
spelling doaj-5065821b3c524cb7aec6064292bc4e782020-11-24T20:58:00ZengFrontiers Media S.A.Frontiers in Molecular Neuroscience1662-50992013-10-01610.3389/fnmol.2013.0003458269Effects of intraventricular methotrexate administration on Cuprizone-induced demyelination in miceAndre Michael Mueller0Adam eNassery1Hana eConlon2Xinhe eLiu3Massimiliano eCristofanilli4Esther eJun5Bo Hyung eYoon6Saud Ahmed Sadiq7Tisch MS Research Center of New YorkAlbert Einstein College of MedicineColumbia University School of NursingTisch MS Research Center of New YorkTisch MS Research Center of New YorkUniversity of California, IrvineTisch MS Research Center of New YorkTisch MS Research Center of New YorkWe previously showed that intrathecal administration of methotrexate slowed disability progression in multiple sclerosis patients with progressive disease. In general MS patients with progressive disease respond poorly to anti-inflammatory therapies. In order to better understand the mechanism by which methotrexate is protective in progressive MS, we analyzed its impact on the non-inflammatory cuprizone-induced demyelination model.When low-dose methotrexate was administered intracerebroventricularly it reduced demyelination and accumulation of GFAP+ reactive astrocytes in the corpus callosum. Administration of methotrexate after the withdrawal of cuprizone neither delayed remyelination nor influenced the number of astrocytes in the corpus callosum suggesting that methotrexate does not interfere with repair processes in the CNS. Moreover, methotrexate increased the expression of IGF1 in vitro and in vivo, a factor known to protect oligodendrocytes and limit the activation of astrocytes. Our studies show that methotrexate has an impact on pathogenic process in a demyelination model whose pathophysiological basis is not primarily related to inflammatory mechanisms, similar to neurodegenerative mechanisms associated with progressive MS. The pronounced inhibitory influence of methotrexate on the accumulation of astrocytes in the corpus callosum suggests that intrathecal methotrexate modulates astroglial activation in progressive MS possibly by promoting CNS production of IGF1.http://journal.frontiersin.org/Journal/10.3389/fnmol.2013.00034/fullAstrocytesMethotrexateMultiple SclerosisEAEIGF1demyelination
collection DOAJ
language English
format Article
sources DOAJ
author Andre Michael Mueller
Adam eNassery
Hana eConlon
Xinhe eLiu
Massimiliano eCristofanilli
Esther eJun
Bo Hyung eYoon
Saud Ahmed Sadiq
spellingShingle Andre Michael Mueller
Adam eNassery
Hana eConlon
Xinhe eLiu
Massimiliano eCristofanilli
Esther eJun
Bo Hyung eYoon
Saud Ahmed Sadiq
Effects of intraventricular methotrexate administration on Cuprizone-induced demyelination in mice
Frontiers in Molecular Neuroscience
Astrocytes
Methotrexate
Multiple Sclerosis
EAE
IGF1
demyelination
author_facet Andre Michael Mueller
Adam eNassery
Hana eConlon
Xinhe eLiu
Massimiliano eCristofanilli
Esther eJun
Bo Hyung eYoon
Saud Ahmed Sadiq
author_sort Andre Michael Mueller
title Effects of intraventricular methotrexate administration on Cuprizone-induced demyelination in mice
title_short Effects of intraventricular methotrexate administration on Cuprizone-induced demyelination in mice
title_full Effects of intraventricular methotrexate administration on Cuprizone-induced demyelination in mice
title_fullStr Effects of intraventricular methotrexate administration on Cuprizone-induced demyelination in mice
title_full_unstemmed Effects of intraventricular methotrexate administration on Cuprizone-induced demyelination in mice
title_sort effects of intraventricular methotrexate administration on cuprizone-induced demyelination in mice
publisher Frontiers Media S.A.
series Frontiers in Molecular Neuroscience
issn 1662-5099
publishDate 2013-10-01
description We previously showed that intrathecal administration of methotrexate slowed disability progression in multiple sclerosis patients with progressive disease. In general MS patients with progressive disease respond poorly to anti-inflammatory therapies. In order to better understand the mechanism by which methotrexate is protective in progressive MS, we analyzed its impact on the non-inflammatory cuprizone-induced demyelination model.When low-dose methotrexate was administered intracerebroventricularly it reduced demyelination and accumulation of GFAP+ reactive astrocytes in the corpus callosum. Administration of methotrexate after the withdrawal of cuprizone neither delayed remyelination nor influenced the number of astrocytes in the corpus callosum suggesting that methotrexate does not interfere with repair processes in the CNS. Moreover, methotrexate increased the expression of IGF1 in vitro and in vivo, a factor known to protect oligodendrocytes and limit the activation of astrocytes. Our studies show that methotrexate has an impact on pathogenic process in a demyelination model whose pathophysiological basis is not primarily related to inflammatory mechanisms, similar to neurodegenerative mechanisms associated with progressive MS. The pronounced inhibitory influence of methotrexate on the accumulation of astrocytes in the corpus callosum suggests that intrathecal methotrexate modulates astroglial activation in progressive MS possibly by promoting CNS production of IGF1.
topic Astrocytes
Methotrexate
Multiple Sclerosis
EAE
IGF1
demyelination
url http://journal.frontiersin.org/Journal/10.3389/fnmol.2013.00034/full
work_keys_str_mv AT andremichaelmueller effectsofintraventricularmethotrexateadministrationoncuprizoneinduceddemyelinationinmice
AT adamenassery effectsofintraventricularmethotrexateadministrationoncuprizoneinduceddemyelinationinmice
AT hanaeconlon effectsofintraventricularmethotrexateadministrationoncuprizoneinduceddemyelinationinmice
AT xinheeliu effectsofintraventricularmethotrexateadministrationoncuprizoneinduceddemyelinationinmice
AT massimilianoecristofanilli effectsofintraventricularmethotrexateadministrationoncuprizoneinduceddemyelinationinmice
AT estherejun effectsofintraventricularmethotrexateadministrationoncuprizoneinduceddemyelinationinmice
AT bohyungeyoon effectsofintraventricularmethotrexateadministrationoncuprizoneinduceddemyelinationinmice
AT saudahmedsadiq effectsofintraventricularmethotrexateadministrationoncuprizoneinduceddemyelinationinmice
_version_ 1716786807742398464